Evaluation of the DuoVT PFA System for Ventricular Tachycardia

Study acronym: EXACT-VT
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoints added 0 → 3 primary endpoints
See other at-risk trials from Abbott Medical Devices

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 10 more changesShow less
    • Phase changed: not specified → not applicable
    • Sponsor changed: [Redacted] to Abbott Medical Devices
    • Trial status changed: Withheld → Recruiting
    • Enrollment changed: None → 50
    • Trial sites expanded: 0 → 5 locations
    • Interventions modified
    • Trial arms changed: 0 → 1
    • Primary and study completion dates: Jul 30, 2027
    • Start date: Sep 29, 2026
    • Study title shortened, about 4 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study is a prospective, non-randomized, single-arm, multicenter study to evaluate the safety and effectiveness of the DuoVT Pulsed Field Ablation (PFA) System.
Trial Details
NCT Number NCT07706712
Lead Sponsor Abbott Medical Devices
Conditions
(from sponsor)		 Ventricular Tachycardia
Related terms Arrhythmias, Cardiac, Tachycardia, Ventricular
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov